JAK2 and Burkitt lymphoma: In the present study, we chose TG101209, a more specific or selective JAK2 kinase inhibitor (at approximately 30-fold greater selectivity for JAK2 than JAK3) [12, 13], as an exploration of anti-Burkitt lymphoma activity.